Insight Molecular Diagnostics Inc. (IMDX)

NASDAQ: IMDX · Real-Time Price · USD
2.580
-0.120 (-4.44%)
At close: Jul 31, 2025, 4:00 PM
2.520
-0.060 (-2.33%)
After-hours: Jul 31, 2025, 4:37 PM EDT
-4.44%
Market Cap73.79M
Revenue (ttm)3.84M
Net Income (ttm)-58.26M
Shares Out 28.60M
EPS (ttm)-3.34
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume39,110
Open2.680
Previous Close2.700
Day's Range2.580 - 2.680
52-Week Range1.922 - 4.750
Beta0.96
Analystsn/a
Price Targetn/a
Earnings DateAug 11, 2025

About ACCD

Insight Molecular Diagnostics Inc. operates as a precision diagnostics company in the United States and internationally. The company develops and commercializes laboratory developed tests, kitted research use only tests, and kitted clinical tests. It is developing DetermaCNI, a blood-based monitoring tool that detects progression early after one cycle cancer treatment; and DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies. The company also offers VitaGraft Kidney, a blood-based tra... [Read more]

Sector Healthcare
Founded 2009
Employees 49
Stock Exchange NASDAQ
Ticker Symbol IMDX
Full Company Profile

Financial Performance

In 2024, IMDX's revenue was $1.88 million, an increase of 25.15% compared to the previous year's $1.50 million. Losses were -$60.93 million, 112.1% more than in 2023.

Financial Statements

News

IMDX World Transplant Congress Late-Breaking Data Potentially Sets New Bar for Predicting Graft Rejection in Kidney Transplant Patients

iMDx first dd-PCR assay to combine relative and absolute measurements of dd-cfDNA into single combined score Data show significantly improved positive predictive value (PPV) for graft rejection, which...

1 day ago - GlobeNewsWire

iMDx to Host Virtual KOL Event to Discuss its In-House dd-cfDNA Testing for Kidney Transplant Patients on August 15, 2025

NASHVILLE, Tenn., July 28, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced that it will host a virtual key opinion leader (KOL) event on Friday, August...

3 days ago - GlobeNewsWire

iMDx Reports Strong Head-to-Head Data in Kidney Transplant Rejection Testing

NASHVILLE, Tenn., June 23, 2025 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics, or iMDx, (Nasdaq: IMDX), today announced positive results from a study evaluating its flagship test kit technology in...

5 weeks ago - GlobeNewsWire

Oncocyte Changes Name to Insight Molecular Diagnostics Inc. (iMDx), Moves Headquarters to Nashville

New name aligns with mission to deliver precision biomarker-based testing for both transplant and oncology care iMDx sponsoring GraftAssureIQ™ research-use-only kits at transplant labs globally Exhibi...

6 weeks ago - GlobeNewsWire

Medicare Boosts Reimbursement for Oncocyte's Flagship Technology

IRVINE, Calif., May 19, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a diagnostics technology company, today provided a positive update on pricing for its next-generation lab-developed test...

2 months ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q1 2025 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q1 2025 Earnings Conference Call May 12, 2025 5:00 PM ET Company Participants Gabby Woody - Executive Assistant, HR Coordinator Josh Riggs - President & Chief Execut...

2 months ago - Seeking Alpha

Oncocyte Reports Q1 2025 Results and Business Progress

IRVINE, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, today published the following letter to shareholders in conjunction with its first quar...

2 months ago - GlobeNewsWire

Oncocyte to Release First Quarter 2025 Results on May 12, 2025

IRVINE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today announced that it will report first quarter 2025 financial results after...

3 months ago - GlobeNewsWire

Oncocyte Provides Positive Update on Clinical Trial Progress

IRVINE, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp., (Nasdaq: OCX), a leading diagnostics technology company, today provided a positive update on its substantial progress toward initiati...

3 months ago - GlobeNewsWire

Oncocyte's Proprietary Assay Demonstrates Long-Term Clinical Validity

Robust data set of 131 patients with 151 kidney biopsies enrolled over four years at Charité University in Berlin Supports market expansion for testing of high-risk patient population New findings adv...

3 months ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q4 2024 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q4 2024 Earnings Conference Call March 24, 2025 5:00 PM ET Company Participants Gabby Woody - Executive Assistant, HR Coordinator Josh Riggs - President and CEO Andr...

4 months ago - Seeking Alpha

Oncocyte to Release Fourth Quarter 2024 Results on March 24, 2025

IRVINE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that it will report fourth quarter 2024 financial results ...

4 months ago - GlobeNewsWire

Oncocyte to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

IRVINE, Calif., Feb. 11, 2025 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a pioneering diagnostics technology company, today announced that Chief Executive Officer Josh Riggs and Chief Financial...

6 months ago - GlobeNewsWire

Oncocyte Appoints Dr. Paul Billings as Consulting Chief Medical Officer

Dr. Billings is a renowned diagnostics specialist with a history of commercializing novel assays in precision medicine Will provide key regulatory and reimbursement support Will assist business develo...

7 months ago - GlobeNewsWire

Oncocyte Expands Market Opportunity for VitaGraft™ Kidney

Medicare coverage expanded following study showing that monitoring with Oncocyte's assay significantly reduces time to rejection diagnosis in patients with newly developed donor-specific antibodies (D...

7 months ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q3 2024 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q3 2024 Results Conference Call November 12, 2024 5:00 PM ET Company Participants Julie Silber - PCG Advisory Josh Riggs - President and CEO Andrea James - CFO Ekke ...

9 months ago - Seeking Alpha

Oncocyte To Announce Third Quarter 2024 Financial Results on Nov. 12

IRVINE, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (Nasdaq: OCX), a diagnostics technology company, announced today that the company will release its third quarter 2024 financial results...

9 months ago - GlobeNewsWire

Oncocyte Announces Participation in the LD Micro Main Event XVII Conference in Los Angeles

IRVINE, Calif., Oct. 16, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corp. (NASDAQ: OCX), a diagnostics technology company, announced today that CEO Josh Riggs is scheduled to present at the 17th annual Main Ev...

10 months ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

OncoCyte Corporation (OCX) Q2 2024 Earnings Call Transcript

1 year ago - Seeking Alpha

Oncocyte Bolsters Executive Team with Key CFO Appointment: PRISM MarketView Highlights Strategic Leadership Move

NEW YORK, June 24, 2024 (GLOBE NEWSWIRE) -- PRISM MarketView, a leader within the financial markets and news community, announces the release of an article highlighting the precision diagnostics compa...

1 year ago - GlobeNewsWire

Favorable Oncocyte VitaGraft Kidney Study Results Published in the New England Journal of Medicine

IRVINE, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation  (Nasdaq: OCX), a precision diagnostics company, today announced that favorable data regarding its lead product VitaGraft™ Kidney ...

1 year ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q1 2024 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q1 2024 Earnings Conference Call May 15, 2024 4:30 PM ET Company Participants Jeff Ramson - Investor Relations Josh Riggs - President and Chief Executive Officer Con...

1 year ago - Seeking Alpha

Oncocyte Reports First Quarter 2024 Financial Results

IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation  (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the quarter ended March 31, 2024.

1 year ago - GlobeNewsWire

OncoCyte Corporation (OCX) Q4 2023 Earnings Call Transcript

OncoCyte Corporation (NASDAQ:OCX) Q4 2023 Results Conference Call April 12, 2024 8:00 AM ET Company Participants Jeff Ramson - PCG Advisory Josh Riggs - President, CEO Conference Call Participants Mi...

1 year ago - Seeking Alpha

Oncocyte Reports Full Year 2023 Financial Results

IRVINE, Calif., April 12, 2024 (GLOBE NEWSWIRE) -- Oncocyte Corporation  (Nasdaq: OCX), a precision diagnostics company, today reported financial results for the year ended December 31, 2023.

1 year ago - GlobeNewsWire